ENTA (STOCKS)
Enanta Pharmaceuticals, Inc
$14.270000
+0.160000 (+1.13%)
Prev close: $14.110000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jay R. Luly
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $413.53M
- Employees
- 131
- P/E (TTM)
- -4.45
- P/B (TTM)
- 3.23
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q1)
|
$-0.42 | $-0.82 | +0.4037 | +49.01% |
|
Sep 2025 (Q4)
|
$-0.87 | $-1.04 | +0.1714 | +16.46% |
|
Jun 2025 (Q3)
|
$-0.85 | $-1.30 | +0.4520 | +34.72% |
|
Mar 2025 (Q2)
|
$-1.06 | $-1.16 | +0.0987 | +8.52% |
Financial Statements
| Revenues | $66.98M |
| Benefits Costs and Expenses | $139.74M |
| Costs And Expenses | $140.04M |
| Nonoperating Income/Loss | $302.00K |
| Operating Expenses | $140.04M |
| Depreciation and Amortization | $4.93M |
| Research and Development | $99.94M |
| Other Operating Expenses | $36.37M |
| Operating Income/Loss | -$73.06M |
| Income/Loss From Continuing Operations After Tax | -$71.54M |
| Income/Loss From Continuing Operations Before Tax | -$72.76M |
| Income Tax Expense/Benefit | -$1.22M |
| Net Income/Loss | -$71.54M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$71.54M |
| Net Income/Loss Available To Common Stockholders, Basic | -$71.54M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.21 |
| Diluted Earnings Per Share | -$3.21 |
| Basic Average Shares | 28,829,336 |
| Diluted Average Shares | 28,829,336 |
| Assets | $329.50M |
| Current Assets | $198.68M |
| Noncurrent Assets | $130.82M |
| Fixed Assets | $34.31M |
| Other Non-current Assets | $96.51M |
| Liabilities | $202.91M |
| Current Liabilities | $44.73M |
| Accounts Payable | $1.89M |
| Wages | $2.40M |
| Other Current Liabilities | $40.44M |
| Noncurrent Liabilities | $158.18M |
| Equity | $126.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $126.59M |
| Liabilities And Equity | $329.50M |
| Net Cash Flow From Operating Activities | -$14.17M |
| Net Cash Flow From Operating Activities, Continuing | -$14.17M |
| Net Cash Flow From Investing Activities | -$75.85M |
| Net Cash Flow From Investing Activities, Continuing | -$75.85M |
| Net Cash Flow From Financing Activities | $42.50M |
| Net Cash Flow From Financing Activities, Continuing | $42.50M |
| Net Cash Flow | -$47.52M |
| Net Cash Flow, Continuing | -$47.52M |
| Comprehensive Income/Loss | -$71.20M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$71.84M |
| Other Comprehensive Income/Loss | -$22.30M |
| Other Comprehensive Income/Loss Attributable To Parent | -$300.00K |